Literature DB >> 2820763

Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence.

J H Trouvin1, P Jacqmin, C Rouch, M Lesne, C Jacquot.   

Abstract

Tabernanthine, an indol alkaloid, is structurally related to carbolines (harmane, harmaline) which, in vitro, displace specific flunitrazepam binding to brain benzodiazepine receptors. In vivo, both tabernanthine and carbolines cause a fine general tremor, suggesting that a possible interaction with benzodiazepine receptors could be involved in the activity of tabernanthine. This hypothesis was validated by the in vitro and in vivo antagonism of benzodiazepine by tabernanthine. In vitro, tabernanthine inhibited specific flunitrazepam binding in a competitive manner with an affinity (IC50 150 microM) in the same range as harmane. Tabernanthine appeared as a benzodiazepine receptor inverse agonist in a discriminant in vitro binding assay. In vivo, the time course of tremorigenic activity was related to the tabernanthine concentration in brain (half-life = 2 h). Moreover, tabernanthine-induced tremor was inhibited reversibly by flunitrazepam or by Ro-15 1788 (an antagonist of benzodiazepine-receptors). These results suggest that part of the action of tabernanthine may be mediated by an interaction at the benzodiazepine receptor level.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820763     DOI: 10.1016/0014-2999(87)90287-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Blood harmane concentrations and dietary protein consumption in essential tremor.

Authors:  E D Louis; W Zheng; L Applegate; L Shi; P Factor-Litvak
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

2.  Relationship between blood harmane and harmine concentrations in familial essential tremor, sporadic essential tremor and controls.

Authors:  Elan D Louis; Wendy Jiang; Marina Gerbin; Mary M Mullaney; Wei Zheng
Journal:  Neurotoxicology       Date:  2010-08-11       Impact factor: 4.294

3.  Blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor: repeat observation in cases and controls in New York.

Authors:  Elan D Louis; Wendy Jiang; Marina Gerbin; Amanda S Viner; Pam Factor-Litvak; Wei Zheng
Journal:  J Toxicol Environ Health A       Date:  2012

4.  Neurochemical and behavioural interactions between ibogaine and nicotine in the rat.

Authors:  M E Benwell; P E Holtom; R J Moran; D J Balfour
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

Review 5.  Environmental epidemiology of essential tremor.

Authors:  Elan D Louis
Journal:  Neuroepidemiology       Date:  2008-08-21       Impact factor: 3.282

6.  Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor.

Authors:  Elan D Louis; Wendy Jiang; Kathryn M Pellegrino; Eileen Rios; Pam Factor-Litvak; Claire Henchcliffe; Wei Zheng
Journal:  Neurotoxicology       Date:  2007-12-27       Impact factor: 4.294

7.  Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity.

Authors:  P M Sweetnam; J Lancaster; A Snowman; J L Collins; S Perschke; C Bauer; J Ferkany
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

Review 8.  Beta-carboline alkaloids and essential tremor: exploring the environmental determinants of one of the most prevalent neurological diseases.

Authors:  Elan D Louis; Wei Zheng
Journal:  ScientificWorldJournal       Date:  2010-09-01

Review 9.  Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Authors:  M Belgers; M Leenaars; J R Homberg; M Ritskes-Hoitinga; A F A Schellekens; C R Hooijmans
Journal:  Transl Psychiatry       Date:  2016-05-31       Impact factor: 6.222

Review 10.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.